Ningbo Sanxing Medical Electric Co., Ltd. (601567.SS) - Deep Dive Research Report

Prepared 2026-07-06. Most recent verified reporting period: Q1 2026 (released ~30 April 2026) and the FY2025 Annual Report (released 25 April 2026). The H1 2026 interim report is due ~late August 2026 and has not yet been released.

A note on reporting cadence and "concalls"

Sanxing is a Shanghai-listed A-share with a December fiscal year-end. It reports four times a year: Q1 (released late April), a half-year interim (late August), Q3 (late October), and the full-year annual report (April of the following year). Chinese A-share issuers do not publish verbatim quarterly earnings-call transcripts in the way US or Indian companies do. What exists instead, and what this report draws on for management commentary, is the combination of (a) the management discussion inside each quarterly and annual filing, (b) the periodic 业绩说明会 (results briefings) held after the annual and interim reports, and (c) 投资者关系活动记录表 (investor-relations activity records) filed with the Shanghai Stock Exchange. Where I attribute forward-looking statements below, I anchor them to the specific reporting period and, where a sell-side note paraphrased a briefing, I flag that. The six reporting periods used throughout are:

• Q1 2026 (released ~30 Apr 2026)
• FY2025 Annual Report (released 25 Apr 2026)
• Q3 2025 (released 30 Oct 2025)
• H1 2025 interim (released 22 Aug 2025)
• Q1 2025 (released 25 Apr 2025)
• FY2024 Annual Report (released 25 Apr 2025)

Section 1: What the Company Does

Ningbo Sanxing Medical Electric does two very different things under one roof, and the name is misleading on both counts. It is not primarily a medical company, and "electric" undersells it. The larger business, roughly three-quarters of revenue, makes the boxes and meters that sit between a power grid and the buildings it feeds: smart electricity meters, distribution transformers, ring main units, switchgear, metering boxes, and the communication modules and software that read them remotely. The smaller business, built by acquisition over the last decade, runs a chain of hospitals in China, most of them rehabilitation hospitals.

The company started in 1986 in Ningbo as an electrical-equipment maker and listed in Shanghai as "Sanxing Electric." Its foundational business was supplying the two Chinese grid monopolies, State Grid Corporation of China and China Southern Power Grid, with smart electricity meters. China ran a nationwide smart-meter rollout across the 2010s, replacing tens of millions of mechanical meters a year with digital ones that report consumption back to the utility automatically. Sanxing became one of a handful of vendors that repeatedly won a 3-4% slice of State Grid's enormous annual tenders. That grid-supplier relationship is the spine of the company.

The "Medical" in the name arrived around 2015-2016, when the controlling shareholder, the Aux Group (奥克斯集团, the same privately held Ningbo conglomerate best known for AUX air conditioners, controlled by founder Zheng Jianjiang), injected a hospital-operating business into the listed company and renamed it Sanxing Medical Electric. The strategic logic was diversification into a defensive, cash-generative healthcare services vertical while the meter business matured. Over the following years the group built what it describes as one of China's largest chains of rehabilitation hospitals.

The core value proposition of the electrical business is boring and durable: grids cannot run without accurate metering and reliable distribution equipment, this gear must be certified and must not fail, and utilities buy it in bulk on repeat tenders from a short list of pre-qualified vendors. The value proposition of the hospital business is capacity in a structurally undersupplied category - rehabilitation and post-acute care for an aging population - operated as a chain to capture scale in procurement and clinical protocols.

What makes the electrical products hard is less any single breakthrough and more the accumulation of qualifications: to win State Grid tenders a vendor must pass type-testing, hold a track record, and manufacture to grid specifications at scale and low cost. To sell the same gear abroad the company must clear each country's certifications (UL in North America, and country-by-country utility approvals in Europe, the Middle East, and Latin America). The last five years have been about carrying that qualified-supplier status overseas, moving up from selling meters to selling higher-value distribution equipment (transformers, ring main units, switchgear) and increasingly building it in-country.

A concrete walk-through: when State Grid runs a smart-meter procurement round, it splits the award across pre-qualified vendors by lot. Sanxing bids, wins a share, manufactures the meters to State Grid's spec at its Ningbo plants, and ships them for installation across a province. The meter then sits on a customer's wall for years, reporting consumption over a communication module back to the utility's metering system, which Sanxing also supplies software for. Abroad, the same motion now includes winning a transformer contract from, say, the Greek public power utility, or a first meter order in Hungary, and increasingly fulfilling it from a local plant in Brazil, Indonesia, Poland, Germany, Mexico, or Kenya rather than shipping from China.

Section 2: Business Segments

Sanxing runs two meaningful segments with almost nothing in common operationally. They share a parent, a listing, and a capital-allocation pool, and little else.

Segment 1: Intelligent Power Distribution and Utilization (智能配用电) - ~78% of FY2025 revenue

This is the original and dominant business. In FY2025 it generated roughly RMB 11.16 billion of revenue, up about 0.4% year on year, at a gross margin of about 27.08%, which fell sharply (down 7.73 percentage points) as domestic meter and distribution pricing came under pressure (FY2025 Annual Report).

What it does. Two sub-lines sit inside it. The "utilization" side (用电) is smart electricity meters, metering boxes, communication modules, and the head-end system software that reads them. The "distribution" side (配电) is the heavier grid gear: distribution transformers, box-type substations, ring main units (including SF6-free "environmental gas" cabinets), medium-voltage switchgear, low-voltage cabinets, and increasingly new-energy adjacent products such as photovoltaic and wind box transformers, energy-storage integrated units, and EV chargers. The company self-developed energy-efficient and miniaturized transformers and a photovoltaic box transformer that received a domestic "first-set" (首台套) certification.

The core capability. Two decades of being a qualified, repeat State Grid and Southern Grid supplier. That status is not buyable; it is earned through type-testing, a delivery track record, and cost competitiveness at scale. Layered on top is the growing ability to replicate that qualification abroad and to localize manufacturing, which most Chinese meter peers have been slower to do.

Why it's a segment. It is the company's roots and its cash engine, technologically and commercially distinct from anything in healthcare.

Competitive position. In State Grid's 2024 smart-meter tenders Sanxing took roughly 3.19% of the award, behind Wasion Group (3.28%) and Dongfang Weston (3.20%) but among the stable top handful; in Southern Grid's 2024 first batch it took about 8.70%, third behind Wasion (9.89%) and Huali (9.09%) (Yinhe/industry note, 2024). Domestically this is a share-stable oligopoly with pricing pressure. The differentiation now is overseas distribution, where Sanxing has moved faster than most peers.

How management talks about it. This is the growth bet dressed as the cash cow: the domestic meter cycle is described as approaching an inflection (a replacement-driven upturn), while overseas distribution is the elastic, long-runway growth vector.

Segment 2: Medical Services (医疗服务) - ~21% of FY2025 revenue

What it does. It builds, operates, invests in, and acquires hospitals, and also does finance leasing tied to hospitals. At the end of 2025 the group ran 38 hospitals, of which 32 were rehabilitation hospitals, with total bed count above 10,000 (FY2025 Annual Report). Management describes the model as "large-general-hospital backstop, strong-specialty chain" (大综合托底，强专科连锁): a core of general-hospital clinical capability anchoring a differentiated chain of rehabilitation specialty hospitals. Its Mingzhou (明州) rehabilitation research institute has produced clinical work including a monograph on critical-care rehabilitation.

FY2025 medical revenue was about RMB 2.98 billion, down 8.8% year on year, hurt by China's medical-insurance payment reforms.

The core capability. Operating a rehabilitation-hospital chain at scale: standardized clinical protocols, procurement leverage, and the capital to build or acquire bed capacity in a category the public system under-serves. The group is positioned as one of China's largest chains of rehabilitation hospitals.

Why it's a segment. Entirely different technology, customer base, regulatory environment (health/insurance regulators, not grid procurement), and economics. It exists because the parent injected it for diversification.

Competitive position. It competes against other private hospital groups and public rehabilitation departments. Its edge is scale and chain standardization; its exposure is total dependence on China's medical-insurance reimbursement regime.

How management talks about it. A defensive, steady-cash vertical whose near-term revenue was dented by DRG/DIP insurance payment reform, with management framing operational-efficiency gains as the path back to steady revenue growth and improving profitability.

Section 3: Products and Business Detail

Utilization (metering) products. Smart single- and three-phase electricity meters, metering boxes, communication/collection modules (concentrators), and head-end system software. This is the highest-volume, most commoditized line, sold overwhelmingly into grid tenders. The technical bar is certification and reliability at industrial scale and low unit cost; the meters must run unattended on a wall for years and report accurately. Sanxing's meters have secured North American UL certification, which opened the US market.

Distribution (grid gear) products. Distribution transformers (including self-developed energy-efficient and miniaturized designs), box-type substations, ring main units including SF6-free environmental-gas cabinets, medium-voltage metal-clad switchgear, and low-voltage cabinets. This is higher-value, higher-margin, more engineered gear, and it is the deliberate move up the value chain that drives the overseas story. The photovoltaic box transformer earned a domestic first-set certification.

New-energy adjacencies. Photovoltaic and wind box transformers, energy-storage integrated units, and EV chargers ("逆储桩" - inverter/storage/charger), sold through a distributor network described as spanning 20-plus countries.

Manufacturing and localization. By the FY2025 report the company operated ten major production bases: three in China plus overseas plants in Brazil (two), Indonesia, Poland, Germany, Mexico, and Kenya, supported by 40-plus sales centers. During 2025 it added a Hungary sales company, a Kenya meter plant, and a Brazil distribution plant (under construction). Overseas capacity had risen to roughly 50% of the total, which management frames as genuine localization rather than export from China - important for tariff exposure, delivery times, and winning contracts that favor local content.

Geographies and milestones. The overseas network spans 70-plus countries. Recent milestones cited in the FY2025 report and 2025 filings include: North American UL meter certification and a first US smart-meter order of about RMB 212 million in July 2025; an Egypt smart-meter order of about RMB 419 million in September 2025; a Greek public power utility transformer contract of about RMB 466 million; first-order breakthroughs in Hungary, Romania, Kyrgyzstan, and Slovakia; and repeat orders in Saudi Arabia, Greece, Brazil, and Mexico. Distribution reached its first European breakthroughs during this stretch.

Order book. Total group order backlog was about RMB 14.80 billion at year-end 2025, up 12.12% year on year; overseas backlog was about RMB 6.39 billion, up 11.1%. By Q1 2026 the overseas distribution order book specifically was about RMB 2.29 billion, up 37.7% year on year (Q1 2026 / Dongwu note).

Section 4: Customers

Who buys. On the electrical side, the anchor customers are the two Chinese grid monopolies, State Grid Corporation of China and China Southern Power Grid, plus their provincial subsidiaries and other domestic power players (companies such as Guodian Power and Longyuan Power appear in 2025-2026 tender wins). Overseas, the customers are national and regional utilities and grid operators across Europe, the Middle East, Latin America, Africa, and now North America - for example the Greek public power utility and utilities in Egypt, Saudi Arabia, Brazil, and Mexico. On the medical side the "customer" is effectively the Chinese patient population paying through the state medical-insurance system.

Who decides and how. Grid purchases run through centralized competitive tenders. The buyer is a utility procurement organization; the criteria are pre-qualification (type-testing and track record), price, and delivery reliability. Sales cycles are long: qualifying to bid takes years, individual tender rounds are periodic, and overseas the first order in a new country is a multi-year business-development effort before repeat orders follow. In healthcare, the buying decision is a patient/physician referral filtered through what medical insurance will reimburse.

Why they choose Sanxing. For grids: it is an already-qualified, reliable, cost-competitive vendor with a delivery track record, and increasingly one that can manufacture locally to satisfy content requirements and shorten lead times. For rehabilitation patients: available beds and standardized clinical care in an undersupplied category.

Switching costs. High on the qualification side, low on any single order. A utility cannot casually swap in an unqualified meter vendor - re-qualification is slow and the cost of a field failure is high - so the incumbent pre-qualified set is sticky. But within that set, individual tenders are won on price, so pricing power is limited and share can move round to round.

Concentration. Historically concentrated on State Grid and Southern Grid domestically. The overseas push is, among other things, a deliberate diversification away from that concentration and away from domestic price deflation. Overseas revenue reached about RMB 2.78 billion in FY2025.

Contract structure. Tender-based framework awards with defined lots and delivery schedules give reasonable near-term visibility, which is why the order backlog (RMB 14.80 billion at year-end 2025) is the key forward indicator management and analysts track. It is not recurring-subscription revenue, but the repeat-tender cadence plus a large backlog gives more predictability than pure spot business. Healthcare revenue is recurring but reimbursement-rate dependent.

Section 5: Competitive Landscape

The Chinese smart-meter and distribution-equipment market is a share-stable oligopoly of a dozen or so qualified vendors, none dominant, all clustered in the low-single-digit-percent range on State Grid awards. Nobody has a runaway lead, which tells you the domestic game is competed on price and qualification, not on a defensible technology moat. The interesting differentiation is now overseas, where the field thins out and localization capability separates the leaders.

Named competitors. The closest and most-cited peer is Wasion (威胜), which operates through Hong Kong-listed Wasion Group Holdings and its Shanghai STAR-listed subsidiary Wasion Information - Wasion led State Grid (3.28%) and Southern Grid (9.89%) 2024 tenders and is furthest along on overseas metering. Others: Linyang Energy (electricity meters plus a solar business), Holley/Huali (华立), Dongfang Weston (东方威思顿), Haixin Electric, XJ Electric / XJ Instruments, State Grid's own Nanjing Rui, plus Goldcard and Suntront on the gas-metering adjacency. On overseas distribution and transformers Sanxing also runs into global majors (Siemens, Schneider, ABB/Hitachi Energy, TBEA) in individual bids, though those are not direct low-cost meter competitors.

The domestic barrier to entry is real but not enormous: it is the qualification and track record needed to bid, which is why the incumbent set is stable and new domestic entrants are rare, but it is not so high that any one player can extract pricing power - hence the margin compression Sanxing showed in 2025. The genuinely higher barrier is overseas: certifications country by country, local manufacturing footprint, and utility relationships built over years. That is where Sanxing's ten global production bases and 70-plus-country network are the closest thing it has to a moat, and where it is ahead of most domestic peers but behind Wasion on pure metering.

Market-cap figures are peer-size references only, as of the dates shown, and move with the market. "—" denotes private/unlisted.

Section 6: Industry

Demand drivers. The electrical business rides two waves. The first is China's smart-meter replacement cycle: meters installed in the 2010s rollout are reaching end of life, and State Grid's annual meter procurement has been running at roughly 90-100 million units, described by industry analysts as a 2024-2025 replacement peak (industry note). The second, larger structural wave is global grid capex: electrification, renewables integration, and aging-grid replacement across Europe, the Middle East, Latin America, and Africa are driving multi-year utility investment in distribution equipment and metering, and Chinese vendors are winning share on cost and delivery. The medical business rides Chinese demographics: an aging population and structural undersupply of rehabilitation and post-acute beds.

Size. Industry research put the China smart-meter market on a path toward roughly RMB 60 billion by 2027 (Global and China Smart Meters Report, 2022). The far larger opportunity is the global distribution-equipment and metering market outside China, which is what the overseas push targets.

Position in the supply chain. Sanxing is a tier-one equipment manufacturer selling directly to utilities. It sits downstream of component and semiconductor suppliers and upstream of the utility. Its move from meters into transformers and switchgear is a move up the value chain into more-engineered, higher-margin gear.

Import/export dynamics. The relevant dynamic is the reverse of import substitution: Chinese meter and distribution vendors, having saturated a price-deflating domestic market, are exporting into and localizing within foreign markets. Sanxing's ~50% overseas capacity share and in-country plants are its answer to tariff risk and local-content preferences.

Regulation. Domestically, grid procurement rules and meter standards shape the metering market, and DRG/DIP medical-insurance payment reform shapes the hospital business (and pressured it in 2025). Overseas, each market's certification regime (UL in North America, EU and national utility standards in Europe) is the gate.

Cyclicality. Grid equipment is tied to utility capex, which is comparatively defensive and policy-driven rather than sharply cyclical, but meter demand is lumpy around replacement cycles and tender timing. Healthcare services are largely non-cyclical but reimbursement-policy sensitive.

Tailwinds and headwinds. Tailwinds: global grid-capex super-cycle, domestic meter replacement peak, electrification and renewables. Headwinds: intense domestic price competition compressing meter and distribution margins, and medical-insurance reform pressure on hospital revenue.

Section 7: Growth Triggers

All items below are drawn from the FY2025 report, Q1 2026 disclosure, and the 2025 interim/Q3 filings and the results briefings paraphrased in sell-side notes around them.

• Overseas distribution order momentum. Overseas distribution backlog reached about RMB 2.29 billion at Q1 2026, up 37.7% year on year, on top of a Q3 2025 figure that management/analysts flagged as up more than 125% year on year (Q1 2026 disclosure; Q3 2025). Repeated across multiple periods as the primary growth vector.

• Domestic meter cycle inflection. Management and analysts frame the domestic meter business as approaching a replacement-driven upturn in revenue and margin (FY2025 report and Q1 2026 briefing).

  Analysts summarizing the Q1 2026 briefing described "in-hand orders supporting revenue conversion, domestic meters reaching an inflection point" (9fzt note on Q1 2026).

• New-country first orders converting to repeat orders. First orders in Hungary, Romania, Kyrgyzstan, and Slovakia during 2025, with repeat orders in Saudi Arabia, Greece, Brazil, and Mexico (FY2025 report). New first orders are the leading indicator of the next leg.

• North America entry. UL certification secured and a first US smart-meter order of ~RMB 212 million booked in July 2025 (FY2025 report). North America is a new market opened, not yet scaled.

• Egypt / Middle East scale-up. ~RMB 419 million Egypt smart-meter order in September 2025 (FY2025 report).

• Localized manufacturing expansion. New Kenya meter plant and Brazil distribution plant (under construction) added in 2025, lifting overseas capacity toward ~50% (FY2025 report). Local capacity is the enabler for winning local-content-sensitive tenders.

• New-energy adjacencies. Energy-storage integrated units, PV/wind box transformers (PV box transformer received a domestic first-set certification), and EV chargers rolling through a 20-plus-country distributor network (FY2025 report).

• Medical efficiency turnaround. Management guides that as hospital operating efficiency improves, medical-services revenue should return to steady growth with improving profitability after the 2025 insurance-reform-driven decline (FY2025 report).

Section 8: Key Risks

Domestic price deflation compressing margins. This is the live, high-probability risk, and it already bit. FY2025 intelligent-distribution gross margin fell 7.73 points to about 27.08% even as revenue was flat, and Q1 2026 net profit fell 65.8% year on year with gross margin down 3.9 points to 25.0% (Q1 2026 note). The mechanism: domestic meter and distribution tenders are won on price among a stable set of qualified vendors, so intensifying competition erodes margin without any single vendor able to hold price. This is a chronic drag, not a one-off.

Overseas execution and geopolitical/tariff exposure. The entire growth thesis rests on overseas distribution scaling. The mechanism of failure: first orders that never convert to repeat volume, local plants (Kenya, Brazil) that ramp slowly or run below capacity, tariff actions or local-content rules that a China-headquartered vendor cannot fully sidestep, or FX and country-payment risk in emerging markets. The ~50% overseas-capacity localization is management's hedge, but building and filling plants across six countries is operationally demanding and capital-hungry.

Medical-insurance reform overhang. DRG/DIP payment reform already cut FY2025 medical revenue 8.8%. The mechanism: reimbursement rates and case-payment caps directly determine hospital revenue, and further tightening or unfavorable local implementation could keep the segment depressed for longer than the "efficiency turnaround" narrative assumes. Management has itself flagged the reform as the cause of the 2025 decline.

Two unrelated businesses, split management attention and capital. A meter/grid-equipment exporter and a rehabilitation-hospital chain have no operational overlap. The mechanism of risk: capital allocated to hospital expansion is capital not compounding in the higher-growth overseas electrical business, and conglomerate structures can obscure the true returns of each leg. The market effectively values two companies stapled together.

Concentration on grid-monopoly buyers and tender timing. Domestically, a large share of revenue depends on State Grid and Southern Grid procurement schedules and lot allocations. A slower-than-expected replacement cycle or a share loss in a tender round directly hits volume.

Parent/related-party governance. Aux Group (~32.4%) and actual controller Zheng Jianjiang (~12.7%) dominate the register. Related-party dynamics (the hospital business itself arrived via the parent) mean minority shareholders depend on the controller's capital-allocation discipline. No share pledges were reported as of the 2025 filings, which is a positive.

Section 9: Walk the Talk

The six reporting periods used: FY2024 (Apr 2025), Q1 2025 (Apr 2025), H1 2025 (Aug 2025), Q3 2025 (Oct 2025), FY2025 (Apr 2026), Q1 2026 (Apr 2026). The most recent, Q1 2026, is within 90 days of today. Because Sanxing does not publish verbatim call transcripts, the assessment below tracks guidance embedded in filings and results briefings against subsequent reported outcomes.

The central, repeated management promise across every one of these periods has been that overseas distribution is the growth engine, and on that specific claim management has delivered with unusual consistency. In the FY2024 report and through 2025, management guided that overseas distribution backlog was inflecting - the FY2024 overseas distribution order book was cited as about RMB 1.2 billion, up roughly 166% year on year. By Q3 2025 the overseas distribution backlog was flagged as up more than 125% year on year (~RMB 2.17 billion), and by Q1 2026 the overseas distribution book was about RMB 2.29 billion, up 37.7% (Q1 2026 note). The specific milestones management pointed to as coming - a first US order after UL certification, a European distribution breakthrough, new-country first orders - actually landed: the ~RMB 212 million US order (July 2025), the ~RMB 466 million Greek transformer contract, the ~RMB 419 million Egypt order (September 2025), and first orders in Hungary, Romania, Slovakia, and Kyrgyzstan. On the overseas story, management has done what it said.

Where the record is weaker is on the domestic and consolidated-profit picture, and here management reads as consistently optimistic. Through 2024 and into 2025 the framing was that domestic meters were reaching a replacement-cycle inflection that would support revenue and margin. What actually happened in FY2025 was flat intelligent-distribution revenue (+0.4%) with gross margin collapsing 7.73 points, and then a Q1 2026 in which consolidated revenue fell 10.8% and net profit fell 65.8%. The "domestic inflection" has been promised repeatedly across periods and has not yet shown up in the numbers; the Q1 2026 briefing again described meters "reaching an inflection point," which is now a repeated forward claim awaiting proof.

On the medical business, management was more candid than promotional: it attributed the FY2025 8.8% revenue decline explicitly to insurance-payment reform rather than spinning it, and framed recovery as contingent on efficiency gains rather than promising a snap-back. That honesty is a credibility positive.

On capital return, management set a clear, quantified policy (2025-2027 plan of at least 45% payout, with a mid-year distribution option) and then actually paid: an RMB 0.89/share final for 2024 (55.12% payout) and an RMB 0.485/share interim for H1 2025. Promise made, promise kept.

Assessment: this is management that delivers on the concrete, checkable overseas milestones and honors its dividend commitments, but that has repeatedly over-anticipated a domestic margin recovery that has not materialized. Credible on strategy and capital return; optimistic on domestic cyclical timing.

Section 10: Shareholder Friendliness Index

Dividends. Sanxing pays and has formalized the commitment. For FY2024 it declared a final dividend of RMB 0.89 per share (RMB 8.90 per 10 shares), totaling about RMB 1.246 billion, a 55.12% payout of FY2024 net profit. It then introduced a mid-year distribution, paying an H1 2025 interim of RMB 0.485 per share (~RMB 679 million) (9fzt / interim disclosure). Alongside, the board adopted a 2025-2027 shareholder-return plan committing to a cash payout ratio of at least 45% of profit each year, with mid-year distributions where conditions allow. The trend is a rising, now-formalized payout with the addition of interim dividends - a genuine improvement in shareholder orientation, above the ~45% floor at the 55% level in FY2024.

Buybacks and dilution. In December 2023 the board approved a buyback of RMB 150-300 million at up to RMB 21.00/share; by June 2024 it had repurchased 13,559,332 shares (0.96% of capital) for RMB 279 million (buyback disclosure). In May 2025 it re-purposed 5,755,371 of those shares from an employee-incentive pool to cancellation, cutting registered capital from 1,411,006,571 to 1,405,251,200 shares, with a further cancellation announced July 2025. Set against a 2024 core-team employee stock ownership plan that issued restricted shares, the net share count over the three years is roughly flat to marginally lower - the buyback-and-cancel offsets incentive dilution rather than shrinking the float meaningfully. This is the only ~90-day-and-older window here; I found no evidence of a large fresh buyback program in the most recent period, only the cancellation tail of the 2023-2024 program.

Verdict: Returns Capital. A formalized ≥45% payout policy actually honored at 55%, plus interim dividends and a buyback used to offset incentive dilution, mark this as a shareholder-friendly capital allocator; the qualifier is that buybacks are modest and net share count is flat rather than shrinking.

Section 11: Insider Activities

No MoatMap insider/buyback data block was injected for this venue. For a Shanghai-listed A-share, insider and major-shareholder transactions are disclosed through Shanghai Stock Exchange announcements (董监高持股变动 for directors/officers, and 5%-shareholder change reports), which are the primary source. I searched these and the aggregated shareholder-change records.

Ownership structure (as of the 2025 filings). The register is controller-dominated and stable:

• Aux Group (奥克斯集团有限公司) held 457,719,653 shares, ~32.44% at H1 2025 (~32.57% at Q3 2025 after cancellations), with zero shares pledged, marked, or frozen (H1 2025 / Q3 2025 reports).
• Zheng Jianjiang (郑坚江), actual controller and Aux founder, held 179,306,730 shares (~12.71%), also with zero pledges.
• The top ten circulating holders held ~65% of the float, indicating tightly held, concentrated ownership.

Recent transactions. Within the last 12 months I did not locate any material open-market purchase or sale by the controlling shareholder, directors, or senior officers in the SSE disclosures reviewed. The only board-level change found was a director resignation and election of an employee director (announced 9 September 2025) - a governance/personnel change, not a share transaction. The company's own actions on its share count in the period were corporate (repurchase-share cancellations in May and July 2025), not individual insider dealing.

Buys - read the signal. No open-market insider buying was identified in the period. There is therefore no bullish cluster-buy signal to report.

Sells - work out the why. No material insider selling was identified either. Notably, neither Aux Group nor Zheng Jianjiang carried any pledged shares across the 2025 filings, which removes a common Chinese-A-share red flag (pledge-driven forced selling); and no controller reduction (减持) plan surfaced.

Net assessment. Insider activity over the trailing 12 months is effectively neutral: a tightly held, controller-dominated register with no reported open-market buying or selling by insiders, no share pledges, and no reduction plans. The absence of insider buying means there is no conviction signal to lean on; the absence of selling and pledges is a mild positive on governance. Read: neutral, with a governance tilt to the positive side. Note that A-share insider-transaction disclosure is less granular and less timely than US Form 4 or EU MAR filings, so smaller officer-level trades may not surface in search; the controller and pledge data, which are the material items, are clear.

Section 12: Scenarios

Bull case. The domestic meter replacement peak plays out as management has long promised, and the "inflection" finally shows in the numbers - domestic meter revenue and margin stabilize and then turn up, ending three years of price-deflation drag. At the same time the overseas distribution engine keeps compounding: the first orders in Hungary, Romania, Egypt, and the US mature into repeat framework awards, the European transformer breakthrough widens beyond Greece, and the Kenya and Brazil plants fill up, pushing overseas toward the higher-margin, faster-growing half of the electrical business. Localized manufacturing insulates the company from tariff fights and wins local-content-sensitive tenders that pure Chinese exporters lose. The medical business, having absorbed the DRG/DIP shock, grinds back to steady growth on efficiency gains and bed-count scale. The market stops valuing the company as a margin-squeezed domestic meter maker with a healthcare distraction and starts valuing the overseas grid-equipment growth it has actually built. Dividends keep rising under the ≥45% policy.

Base case. The most likely path is bifurcated, roughly what the last two years already show. Overseas distribution continues to grow order backlog at a healthy clip and becomes a steadily larger share of the mix, delivering the volume growth the group needs. But domestic pricing stays competitive, so consolidated margins recover only slowly and unevenly - the FY2025 margin compression and the weak Q1 2026 profit are digested rather than instantly reversed. The medical business stabilizes near current levels as insurance reform is absorbed, contributing steady but unexciting cash rather than growth. Management delivers roughly on its overseas milestones, keeps paying a ~45-55% payout with interim dividends, and the story remains "overseas growth offsetting domestic deflation," with the consolidated result depending each quarter on which force is winning. Nothing breaks; nothing dramatically re-rates.

Bear case. The domestic "inflection" keeps being promised and keeps not arriving - the replacement cycle disappoints or price competition among the stable vendor set intensifies further, and domestic meter/distribution margins keep grinding lower, as Q1 2026's 65.8% profit drop hints they can. Overseas, execution stumbles: first orders fail to convert to repeat volume, the Kenya and Brazil plants ramp slowly and sit under-utilized, or tariff/local-content actions and emerging-market payment risk blunt the expansion just as the capital has been spent. The medical segment stays depressed as insurance reform tightens rather than eases, turning a defensive cash leg into a drag on capital and attention. In that world the conglomerate discount widens: two unrelated, underperforming businesses competing for capital, with the growth thesis (overseas distribution) not yet big enough to carry consolidated earnings while the legacy domestic business deflates underneath it.